Hemophilia B: Therapeutic Updates, Emerging Therapies, and Barriers to Care

Hemophilia B: Therapeutic Updates, Emerging Therapies, and Barriers to Care is organized by ScientiaCME.

Release Date: May 08, 2018
Expiration Date: May 08, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.00 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-021-H01-P. ACPE Accreditation effective 05/10/18, expires 05/10/20. 

Description:
In this online CME self-learning program:
Hemophilia encompasses a small group of genetic disorders that impair the body’s hemostatic self-regulation mechanisms. Hemophilias A and B, which describe deficiencies in clotting factors VIII and IX, respectively, occur in approximately 1 in 5,000 live male births. Signs and symptoms are not always readily detectable and often escape notice for the first several months of life, but the effects can be life-threatening and may include intracranial hemorrhage, severe bleeding in other organ systems and superficial tissue, and muscoskeletal and intraarticular injury.

The mainstay of hemophilia treatment is clotting factor replacement therapy in the setting of comprehensive care. Recombinant synthesis and blood donor screenings have significantly reduced the once common concern about transmission of infection through pooled donor products, although the development of clotting factors antibodies remain a concern. Other treatments available or in development include other hemostatic and antifibrinolytic medicines and gene therapy.

One contemporary barrier to the optimal treatment of patients may be variability in care due to therapeutic controversies including when to initiate prophylactic therapy and may merit continuing educational programming for strategy elucidation. Another gap is the challenge of continued adherence to therapy, and the healthcare professional may benefit from learning strategies aimed at maintaining and preserving the patient’s commitment to his or her own therapy in the face of obstacles including the necessity for frequent administration.

Objectives:
By the end of the session the participant will be able to:
• Describe the pathophysiology of hemophilia B, with an emphasis on characteristics that play a role in determining the staging, prognosis, and diagnosis
• Describe the benefits of prophylactic vs. on-demand clotting factor regimens in patients with hemophilia and apply them in patient cases
• Describe emerging therapies in the treatment of hemophilia B
• Individualize treatments in patients with hemophilia B by taking into account treatment modalities, recent clinical trial evidence, and barriers to care , including inhibitors